GlucoTrack (GCTK) investor relations material

Company overview and business model

• Focuses on developing an implantable continuous blood glucose monitor (CBGM) for Type 1 and insulin-dependent Type 2 diabetes, aiming for improved accuracy, convenience, and implant longevity compared to current solutions.

• Transitioned from a non-invasive earlobe sensor (CE Mark approved, now withdrawn) to fully implantable CBGM technology, with recent successful preclinical and first-in-human studies.

• Holds ISO13485 certification for medical device quality management and is preparing for U.S. FDA IDE discussions and a long-term feasibility study outside the U.S.

Financial performance and metrics

• As of June 30, 2025, had cash and cash equivalents of $9,555 and an accumulated deficit of approximately $144,039,000.

• Net tangible book value per share as of June 30, 2025, was $0.01; after the offering, as adjusted, would be $7.26 per share, with immediate dilution of $0.19 to new investors.

• Has incurred recurring losses and negative cash flows since inception, raising substantial doubt about its ability to continue as a going concern.

Use of proceeds and capital allocation

• May receive up to $20.0 million in gross proceeds from sales of common stock to Sixth Borough under the Purchase Agreement, to be used for working capital and general corporate purposes.

• Management has broad discretion over the use of proceeds, which may be allocated to purposes not currently contemplated.